AMPH
Amphastar Pharmaceuticals, Inc.NASDAQHealthcare$20.45+1.04%ClosedMarket Cap: $939.7M
As of 2026-04-06
Valuation
P/E (TTM)
9.58
PEG
—
P/B
1.20
P/S
1.31
EV/EBITDA
7.35
DCF Value
$94.23
FCF Yield
12.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
49.5%
Operating Margin
19.5%
Net Margin
13.6%
ROE
12.8%
ROA
6.0%
ROIC
7.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $183.1M | 46.8% | $35.6M | $24.4M | $0.51 | — |
| FY 2025 | $719.9M | 49.5% | $140.4M | $98.1M | $2.03 | — |
| Q3 2025 | $191.8M | 51.4% | $25.3M | $17.4M | $0.37 | — |
| Q2 2025 | $174.4M | 49.6% | $42.2M | $31.0M | $0.64 | — |
| Q1 2025 | $170.5M | 50.0% | $37.3M | $25.3M | $0.51 | — |
| Q4 2024 | $186.5M | 46.5% | $45.1M | $38.0M | $0.74 | — |
| FY 2024 | $732.0M | 51.1% | $205.4M | $159.5M | $3.06 | — |
| Q3 2024 | $188.8M | 54.0% | $57.0M | $40.4M | $0.78 | — |
| Q2 2024 | $182.4M | 52.2% | $55.2M | $37.9M | $0.73 | — |
| Q1 2024 | $171.8M | 50.8% | $48.0M | $43.2M | $0.81 | — |
| Q4 2023 | $178.1M | 54.0% | $54.0M | $36.2M | $0.68 | — |
| FY 2023 | $644.4M | 54.5% | $197.0M | $137.5M | $2.60 | — |